Exploring the microbiome in patients with advanced biliary tract cancer in a first-line study of durvalumab (MEDI4736) in combination with cisplatin/gemcitabine (ABC-12)

Research summary

In this study,a new drug will be used,durvalumab,to try and block this signal to increase the immune response,in combination with standard of care cisplatin/gemcitabine chemotherapy. Durvalumab is an antibody (a protein produced by the body’s defense system) and it is hoped that by blocking this signal,the immune cells will once again be able to prevent or slow down cancer growth. This drug combination has been shown in a large clinical trial to increase survival in patients with BTC where surgery is not an option. The aim will be to recruit 70 patients across 10 UK sites over 12 months,with a 12 month follow up period.

Principal Investigator

Dr Paul Miller

Contact us

Email: latephaseoncology@ouh.nhs.uk

IRAS number

1005274